Cargando…

The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience

Background. Infliximab (IFX) therapeutic drug monitoring (TDM) allows for objective decision making in patients with inflammatory bowel disease (IBD) and loss of response. Questions remain about whether IFX TDM improves outcomes. Methods. Patients with IBD who had IFX TDM due to concerns for loss of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitchell, Robert A., Shuster, Constantin, Shahidi, Neal, Galorport, Cherry, DeMarco, Mari L., Rosenfeld, Gregory, Enns, Robert A., Bressler, Brian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121455/ https://www.ncbi.nlm.nih.gov/pubmed/27957480 http://dx.doi.org/10.1155/2016/5203898

Ejemplares similares

Assessment of Capsule Endoscopy Utilizing Capsocam Plus in Patients With Suspected Small Bowel Disease Including Pilot Study With Remote Access Patients During Pandemic
por: Enns, Chasyn, et al.
Publicado: (2021)

Rate of Corticosteroid-Induced Mood Changes in Patients with Inflammatory Bowel Disease: A Prospective Study
por: Ou, George, et al.
Publicado: (2018)

Capsule Endoscopy for Obscure Gastrointestinal Bleeding in Patients with Comorbid Rheumatic Diseases
por: Shahidi, Neal, et al.
Publicado: (2014)

Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia
por: Ou, George, et al.
Publicado: (2016)

Comparing the Real-World Effectiveness of High- Versus Low-Volume Split Colonoscopy Preparations: An Experience Through the British Columbia Colon Cancer Screening Program
por: Lee, Joseph G H, et al.
Publicado: (2020)

Characteristics of Patients with Colonic Polyps Requiring Segmental Resection
por: Mitchell, Robert A., et al.
Publicado: (2018)

Diagnosis and Management of Barrett's Esophagus: A Retrospective Study Comparing the Endoscopic Assessment of Early Esophageal Lesions in the Community versus a Specialized Center
por: Rayner-Hartley, Erin, et al.
Publicado: (2016)

Benefit of Capsule Endoscopy in the Setting of Iron Deficiency Anemia in Patients Above Age 65
por: Lee, Joseph G, et al.
Publicado: (2018)

Internet-Based Patient Education Prior to Colonoscopy: Prospective, Observational Study of a Single Center’s Implementation, with Objective Assessment of Bowel Preparation Quality and Patient Satisfaction
por: Trasolini, Roberto, et al.
Publicado: (2019)

FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease
por: Rosenfeld, Greg, et al.
Publicado: (2016)

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

Repeat Endoscopic Ultrasound-Guided Fine-Needle Aspiration in Patients with Suspected Pancreatic Cancer: Diagnostic Yield and Associated Change in Access to Appropriate Care
por: Mitchell, Robert A., et al.
Publicado: (2016)

Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort
por: Gros, Beatriz, et al.
Publicado: (2023)

Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
por: Nakagawa, Tomoo, et al.
Publicado: (2019)

A175 REAL-WORLD EXPERIENCE ON SWITCHING FROM ADALIMUMAB TO BIOSIMILARS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE – AN OBSERVATIONAL STUDY FROM THREE TERTIARY CARE CENTRES
por: Bedi, H, et al.
Publicado: (2023)

Infliximab in inflammatory bowel disease
por: Papamichael, Konstantinos, et al.
Publicado: (2019)

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2019)

Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis
por: Sakkat, Abdullah, et al.
Publicado: (2022)

Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study
por: Scavone, Cristina, et al.
Publicado: (2018)

A descriptive analysis of real-world treatment patterns of innovator (Remicade(®)) and biosimilar infliximab in an infliximab-naïve Turkish population
por: Yazici, Yusuf, et al.
Publicado: (2018)

Safety and efficacy of transitioning inflammatory bowel disease patients from intravenous to subcutaneous infliximab: a single-center real-world experience
por: Jeffrey, Angus W., et al.
Publicado: (2023)

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
por: Yazici, Yusuf, et al.
Publicado: (2018)

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
por: Lichtenstein, Gary R, et al.
Publicado: (2018)

Real-World Experience With Proactive Therapeutic Drug Monitoring During Infliximab Reintroduction
por: Normatov, Inessa, et al.
Publicado: (2021)

Improvement of Endoscopic Reports with Implementation of a Dictation Template
por: Harris, Natasha, et al.
Publicado: (2019)

Does infliximab increase complications after surgery for inflammatory bowel disease?
por: Holubar, Stefan D, et al.
Publicado: (2009)

When trainees reach competency in performing endoscopic ultrasound: a systematic review
por: Shahidi, Neal, et al.
Publicado: (2017)

Inflammatory bowel disease of the lung: The role of infliximab?()
por: Hayek, Adam J., et al.
Publicado: (2015)

A96 IMPROVING AUTOMATED TELEHEALTH SERVICES TO MEET THE NEEDS OF PATIENTS AND HEALTHCARE PROFESSIONALS
por: Calman T'ien, L, et al.
Publicado: (2023)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease
por: Abej, Esmail, et al.
Publicado: (2016)

Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)
por: Abraham, Bincy, et al.
Publicado: (2022)

Comparative Effectiveness of Vedolizumab vs. Infliximab Induction Therapy in Ulcerative Colitis: Experience of a Real-World Cohort at a Tertiary Inflammatory Bowel Disease Center
por: Allamneni, Chaitanya, et al.
Publicado: (2018)

Management of inflammatory bowel disease in poor responders to infliximab
por: Guerra, Iván, et al.
Publicado: (2014)

Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events
por: Araujo, Daniel V., et al.
Publicado: (2021)

Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study
por: Fautrel, Bruno, et al.
Publicado: (2023)

Infliximab-Induced Hypothyroidism: A Novel Case and Postulations concerning the Mechanism
por: Cerniglia, Brett, et al.
Publicado: (2013)

A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis
por: Haque, Emily K., et al.
Publicado: (2020)

Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China
por: Shi, Ji-Hao, et al.
Publicado: (2020)

A75 AUTOMATED FOLLOW-UP USING A PATIENT-GUIDED COMPLICATION TRACKING SYSTEM (PACTS): AN UPDATE ON PROGRESS
por: Calman T’ien, L, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ivqg4c8ne26vu9dgmrlvhqr3hh